Abstract
2.48-68.39, p= 0.024). A significant decrease in mean anti-CMV titers (baseline vs. day 30) was observed in both groups (CMV disease: 20419±14483 vs. 14235±11963, p= 0.044; no-CMV disease: 23232±2134 vs. 18247±1747, p< 0.001). There were no significative differences in mean specific anti-CMV titers between both groups in the analyzed study points. Conclusion: In conclusion, CMV-seropositive heart transplant recipients at risk for CMV disease can be identified based on readily assessable immunological biomarkers. Preventive strategies may be selectively targeted toward these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have